Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SHY2 as a node in the regulation of root meristem development by auxin, brassinosteroids, and cytokinin.

Journal of integrative plant biology·2020
Same author

Dynamic tailoring of an optical skyrmion lattice in surface plasmon polaritons.

Optics express·2020
Same author

High-Efficiency, Broadband, Near Diffraction-Limited, Dielectric Metalens in Ultraviolet Spectrum.

Nanomaterials (Basel, Switzerland)·2020
Same author

Experimental Examination of Electrical Characteristics for Portland Cement Mortar Frost Damage Evaluation.

Materials (Basel, Switzerland)·2020
Same author

Synthesis of Imidazole-Based Medicinal Molecules Utilizing the van Leusen Imidazole Synthesis.

Pharmaceuticals (Basel, Switzerland)·2020
Same author

Mutagenesis for Improvement of Activity and Stability of Prolyl Aminopeptidase from Aspergillus oryzae.

Applied biochemistry and biotechnology·2020

Related Experiment Video

Updated: Mar 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy.

Wantong Song1, Zhaohui Tang1, Dawei Zhang1

  • 11. Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China;

Theranostics
|May 25, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces a novel nanocarrier drug combination therapy for solid tumors, using vascular disrupting agents (VDAs) and cytotoxic drugs to eliminate cancer cells effectively. The "cannon and pawn" strategy significantly inhibited tumor growth in preclinical models.

Keywords:
combinationcytotoxic drugsnanocarriertumor therapy.vascular disrupting agents

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Experiment Videos

Last Updated: Mar 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Area of Science:

  • Oncology
  • Nanomedicine
  • Pharmacology

Background:

  • Nanocarrier-based anti-tumor drugs offer improved retention and reduced side effects for solid tumor treatment.
  • Limited drug penetration in tumor tissues remains a significant challenge for nanocarrier efficacy.
  • Combination therapy strategies are needed to overcome drug penetration limitations and enhance therapeutic outcomes.

Purpose of the Study:

  • To develop and evaluate a nanocarrier-based combination therapy using vascular disrupting agents (VDAs) and cytotoxic drugs for solid tumors.
  • To investigate the synergistic effect of combretastatin A-4 (CA4) and doxorubicin (DOX) delivered via nanocarriers.
  • To assess the efficacy of this dual-drug nanocarrier system in reducing tumor burden and inhibiting tumor growth.

Main Methods:

  • A nanocarrier system co-delivering combretastatin A-4 (CA4) and doxorubicin (DOX) was designed.
  • The combination therapy was evaluated in murine C26 colon tumor models.
  • Tumor cell eradication and tumor growth inhibition were assessed in both small and large solid tumor models (C26 and 4T1).

Main Results:

  • The nanocarrier-based combination therapy eradicated over 94% of tumor cells in a murine C26 colon tumor model.
  • Weekly injections of the combination therapy significantly inhibited tumor growth.
  • Effective tumor growth inhibition was observed in large solid tumor models (approx. 250 mm(3)) of C26 and 4T1 tumors.

Conclusions:

  • The proposed
  • cannon and pawn
  • nanocarrier combination strategy effectively eliminates solid tumor cells.
  • This approach provides a promising therapeutic option for solid tumor treatment with significant tumor growth inhibition.
  • Further development of this dual-drug nanocarrier system could advance cancer therapy.